Published in Pharma Investments, Ventures and Law Weekly, September 19th, 2004
Revenues were $11.1 million for the second quarter, a 25% increase compared to revenues of $8.8 million for the second quarter of 2003. Net loss for the quarter decreased 14% to $3.6 million, or $0.18 per diluted share as compared to $4.2 million, or $0.21 for the comparable period last year.
For the 6 months ended June 30, 2004, revenue increased 5% to $22.7 million. Net loss was $4.8 million, or $0.24 per diluted share, a 20% increase from the $4.0 million, or $0.20 per diluted share, in 2003. The increase in net loss is primarily attributable to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly